Pharma’s Words Of Wisdom For Prospective Biotech Partners

Low Prices Not Changed The Foundations Of Dealmaking

Stay patient and concentrate on building trust rather than the bank balance was one of the key pieces of advice offered by business development heads at Regeneron and Eli Lilly to start-ups attending the recent BIO-Europe meeting.

BIO Leipzig
There were over 4,000 attendees at BIO-Europe • Source: Kevin Grogan

A return to sensible valuations has helped increase the number of pacts between pharma and biotechs but experienced dealmakers from the bigger players have stressed that price is not the main driver when they go looking for partnerships.

Speaking at the recent BIO-Europe congress in Leipzig, Germany, the continent's largest biopharma partnering meeting with over 4,000 attendees, Nouhad...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.